GeoVax Labs Stock Performance
| GOVX Stock | USD 1.09 -0.06 -5.22% |
Risk-Adjusted Performance
Weak
Weak | Strong |
During the last 90 trading days, GeoVax Labs produced negative risk-adjusted performance, which signals weak return efficiency for investors with long positions. When applied, this score supports evaluation of raw price movement versus actual return efficiency. GeoVax Labs has delivered negative risk-adjusted performance over recent months. The stock's basic indicators have failed to convert volatility into returns, and current dislocation adds further downside pressure for the company's investors. Learn More
Last Split Factor 1:25 | Dividend Date 2020-09-25 | Last Split Date 2026-01-12 |
1 | Geo Vax Labs Approaches Critical Clinical Milestones - AD HOC NEWS | 02/11/2026 |
2 | Geo Vax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over | 02/17/2026 |
3 | Geo Vax Announces Oncology Advisory Board to Advance Gedeptin Development Across Solid Tumors | 02/24/2026 |
4 | Geo Vax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox Smallpox Vaccine | 03/11/2026 |
5 | Acquisition by Kollintzas Dean G of 300000 shares of Geo Vax Labs at 0.0266 subject to Rule 16 b-3 | 03/24/2026 |
6 | Geo Vax Provides Update on GEO-MVA Program | 03/25/2026 |
7 | 12 Health Care Stocks Moving In Fridays After-Market Session | 04/10/2026 |
8 | GOVX Forecast, Price Target Analyst Ratings GEOVAX LABS INC - Chart Mill | 04/17/2026 |
Performance Related Modules
Earnings links to analyst estimate history and revisions, Ownership shows shareholder mix, Profitability focuses on margin and return ratios, Liquidity covers cash-flow strength and short-term funding capacity, and Fundamentals groups the broader financial ratio set.
Relative Risk vs. Return Landscape
If you had invested $ 295.00 in GeoVax Labs on January 26, 2026 and sold it today you would have lost $ 186.00 from holding GeoVax Labs or given up 63.05% of portfolio value over 90 days. GeoVax Labs does not currently generate positive expected returns and carries 5.8285% risk (volatility on return distribution) over a 90-day horizon. In relative terms, GeoVax exhibits above-average volatility, exceeding roughly 48% of comparable stocks, and GOVX has trailed 99% of traded instruments in return over the 90-day horizon. Expected Return |
| Risk |
Target Price Odds to finish over Current Price
Price convergence toward a historical mean is a well-documented pattern for stocks like GeoVax Stock. Although this tendency is a useful forecasting input, some instruments remain persistently mispriced before market correction.
| Current Price | Horizon | Target Price | Odds moving above the current price in 90 days |
| 1.09 | 90 days | 1.09 | about 88.11 |
Our distribution model estimates the likelihood of GeoVax Labs moving above the current price in 90 days from now at about 88.11 . Past return patterns over this horizon reflect a distribution that has favored above-current-price scenarios. (This GeoVax Labs distribution emphasizes the price range most consistent with recent behavior in GeoVax Stock over a 90-day period).
GeoVax Labs Price Density |
| Price |
Predictive Modules for GeoVax Labs
Investors apply quantitative and fundamental models to forecast GeoVax Labs within the stock market. Combining results from different methods frames the confidence level warranted by GeoVax Labs predictions.Statistical evidence for mean reversion in GeoVax Labs' appears through its tendency to revert after extreme valuations. Under mean reversion theory, GeoVax Labs' price extremes are viewed as temporary dislocations that may self-correct.
Primary Risk Indicators
Significant market corrections and rallies over the last two decades have made the stock market challenging for GeoVax Labs investors. Dramatic market moves have periodically reshaped the risk landscape for holders of GeoVax Labs.α | Alpha over Dow Jones | -1.3354 | |
β | Beta against Dow Jones | 0.80 | |
σ | Overall volatility | 0.61 | |
Ir | Information ratio | -0.2253 |
Investor Alerts and Insights
Tracking GeoVax Labs through automated alerts focuses attention on the most impactful stock developments. Reviewing GeoVax Labs notifications is an efficient way to stay current on technical patterns and fundamental changes.| GeoVax Labs generated a negative expected return over the last 90 days | |
| GeoVax Labs has high historical volatility and very poor performance | |
| GeoVax Labs has some characteristics of a very speculative penny stock | |
| GeoVax Labs has a very high chance of going through financial distress in the upcoming years | |
| GOVX reported previous year's revenue of 2.49 M. Net Loss for the year was -21.46 M with loss before overhead, payroll, taxes, and interest of -15.63 M. | |
| GeoVax Labs currently holds about 30.9 M in cash as of latest reporting with -21.47 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.25, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| GeoVax Labs has a poor financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Disposition of 11982 shares by Hrt Financial Lp of Aditxt at 0.3 subject to Rule 16 b-3 |
Price Density Drivers
Several forces contribute to GeoVax Labs' price dynamics, including buyer and seller positioning dynamics and market conditions. Monitoring GeoVax Labs' price density drivers provides context for distinguishing fundamental from tactical price moves.
| Common Stock Shares Outstanding | 958.4 K | |
| Cash And Short Term Investments | 3.1 T |
GeoVax Labs Fundamentals Growth
Market participants price GeoVax Stock based on their assessment of GeoVax Labs' financial trajectory. Revenue and earnings growth, profitability metrics, and debt levels form the core fundamentals driving GeoVax Stock.
| Return On Equity | -4.84 | ||||
| Return On Asset | -1.87 | ||||
| Operating Margin | -8.69 | ||||
| Current Valuation | 953.72 K | ||||
| Shares Outstanding | 2.89 M | ||||
| Price To Earnings | -1.25 X | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 1.27 X | ||||
| Revenue | 2.49 M | ||||
| Gross Profit | -15.63 M | ||||
| EBITDA | -21.64 M | ||||
| Net Income | -21.46 M | ||||
| Cash And Equivalents | 30.9 M | ||||
| Cash Per Share | 1.25 X | ||||
| Total Debt | 843.17 B | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 9.51 X | ||||
| Book Value Per Share | 2.21 X | ||||
| Cash Flow From Operations | -21.47 M | ||||
| Earnings Per Share | -22.40 X | ||||
| Market Capitalization | 3.15 M | ||||
| Total Asset | 6.34 T | ||||
| Retained Earnings | -150.82 T | ||||
| Working Capital | 3.38 M | ||||
| Current Asset | 1.24 M | ||||
| Current Liabilities | 126.99 K | ||||
Performance Metrics & Calculation Methodology
GeoVax Labs risk-adjusted performance measures whether returns compensate for the volatility borne by holders. Adjusting for volatility reveals whether realized returns were earned efficiently or through excessive exposure. GeoVax Labs shows ROE of -4.84%, ROA of -1.87% (TTM) vs 0.0% (last reported).
GeoVax Labs metrics are compiled from periodic company reporting and market reference feeds and normalized before display. Return and risk statistics are calculated from historical price series.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board